Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Key Highlights
- ➤$3.6 million annual savings plan begins in Q4 2026 (VVOS)
- ➤Las Vegas referrals rose approximately 3-fold from June through September 27
- ➤EEG initiative projected at $1.5-$3.0 million annualized Q4 run rate
- ➤RPM program expected to add up to $3.5 million annualized by Q1 2027
- ➤Management targets cash-flow positivity by late 2026 or early 2027
Expert Statements
R. Kirk Huntsman, Chairman and Chief Executive Officer of Vivos Therapeutics
“Our management team is laser focused on all of our restructuring and revenue growth initiatives. Perhaps the most compelling is our ongoing conversions and replacement of legacy IT and software systems and infrastructure that dramatically leverage AI and allow us significant and material labor savings.”
LITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other breathing and sleep disorders, today announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6 million annually, beginning in Q4 2026. Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negotiated contract savings, and more. The Company expects the full measure of cuts to take place in the fourth quarter of 2026.
In addition to the announced expense reductions, management has also pursued a number of revenue growth initiatives that are beginning to deliver meaningful financial returns. Consistent with the Company’s previously announced growth, referrals into the Company’s Las Vegas Sleep and Airway Medicine Centers continued to rise approximately 3-fold from the first of June through September 27. Revenue from the recent surge in referrals is expected to begin showing up in the fourth quarter and into 2027.
Get started
Create a free account to read the full story.